In a study including 779 colon cancers of all stages and taking into account MS and BRAF status, Wirta et al. [61] found that IS composed of CD3+ and CD8+ TILs was not superior to TNM staging as an independent prognostic factor, yet it could discriminate patients survival within each stage, particularly in stage IIa. The gene discussed is BRAF; the disease is colonic neoplasm.